Sciwind Biosciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3001 Bishop Dr Ste 300, San Ramon, Calif...Website
www.sciwindbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Sciwind Biosciences
Headquartered in Hangzhou, China, Sciwind Biosciences is a clinical-stage biopharmaceutical company.Explore more
Sciwind Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sciwind Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sciwind Biosciences
Product Launch: Get notified when Sciwind Biosciences launches new products
Click to see if Sciwind Biosciences had a recent Job posting/layoffs
Check if Sciwind Biosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Sciwind Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Sciwind Biosciences is spiking on competitors!
Earning: See what the market has to say on Sciwind Biosciences recently announced quarterly report
Funding: Get notified immidiatlly once Sciwind Biosciences has new funding data
Recommended Actions
Find VP level buyers at Sciwind Biosciences
Find 2 more new buyers
Company Profile Activity
Activity Insights
Sciwind Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sciwind Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sciwind Biosciences.
Sciwind Biosciences financials insights
Gather financial insights about Sciwind Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series C
$70M
Sciwind Biosciences Tech Stack
A closer look at the technologies used by Sciwind Biosciences
Sciwind Biosciences News & Media
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. SciwindSciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist. The number of diabetes patients in ChinSciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Conducted in adult T2DM patients with inadequate glycemic control after diet and exercise intervention, the results demonstrate that ecnoglutide injection — potentially the world's first long-acting cAMP-biSciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio
HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited ("Verdiva"), a clinical-stage biopharmaceutical company specialized i
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sciwind Biosciences
Sign Up For FreeTo access detailed company insights
Headquartered in Hangzhou, China, Sciwind Biosciences is a clinical-stage biopharmaceutical company.... Read More
